bearish

Natco Pharma

Natco Pharma Limited: Covid Drags FY21; New Launches to Drive FY22

145 Views21 Jun 2021 15:33
Broker
Natco is a leading player in the domestic oncology segment. Covid related disturbances and pricing pressure notwithstanding, we expect momentum in oncology segment to be decent
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 1-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
ICICI Securities Limited
External broker reports(aggregated public sources)
ICICI Securities Ltd
IndiaEquity Bottom-Up
Price Chart(Sign Up to Access)
analytics-chart
  • Natco Pharma Limited: Covid Drags FY21; New Launches to Drive FY22
    21 Jun 2021
x